{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:20:28Z","timestamp":1787685628195,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41375-026-03035-9","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:25:19Z","timestamp":1783927519000},"page":"1968-1976","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9570-5542","authenticated-orcid":false,"given":"Gonzalo","family":"Carre\u00f1o-Tarragona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Gil-Manso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-3113","authenticated-orcid":false,"given":"Juan Carlos","family":"Hern\u00e1ndez-Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-8195","authenticated-orcid":false,"given":"Jos\u00e9 Carlos","family":"Mart\u00ednez-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Bellosillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4380-6391","authenticated-orcid":false,"given":"Ra\u00fal","family":"P\u00e9rez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-3243","authenticated-orcid":false,"given":"Francisca","family":"Ferrer-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Arellano-Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Angona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4752-0815","authenticated-orcid":false,"given":"Valent\u00edn","family":"Garc\u00eda-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4875-3438","authenticated-orcid":false,"given":"Mar\u00eda Soledad","family":"Noya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1756-376X","authenticated-orcid":false,"given":"\u00c1ngela","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1713-7110","authenticated-orcid":false,"given":"Lurdes","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Sen\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pastor-Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel","family":"Mata-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-8441","authenticated-orcid":false,"given":"Mar\u00eda Luz","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7555-3361","authenticated-orcid":false,"given":"Beatriz","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"V\u00e9lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mart\u00ednez-Bilbao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-886X","authenticated-orcid":false,"given":"Rafael","family":"Colmenares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6233-5912","authenticated-orcid":false,"given":"Juan Manuel","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"P\u00e9rez-Encinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6623-780X","authenticated-orcid":false,"given":"Gonzalo","family":"Caballero-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0526-4036","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Santaliestra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Raya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Blanco-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9661-9371","authenticated-orcid":false,"given":"Jes\u00fas Mar\u00eda","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-8353","authenticated-orcid":false,"given":"Rosa","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-4619","authenticated-orcid":false,"given":"Alberto","family":"\u00c1lvarez-Larr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the MPN Spanish Group (GEMFIN)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"3035_CR1","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1182\/blood.2022017578","volume":"141","author":"DL Paz","year":"2023","unstructured":"Paz DL, Kralovics R, Skoda RC. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023;141:1909\u201321.","journal-title":"Blood"},{"key":"3035_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129:667\u201379.","journal-title":"Blood"},{"key":"3035_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"3035_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"3035_CR5","doi-asserted-by":"crossref","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99:697\u2013718.","DOI":"10.1002\/ajh.27216"},{"key":"3035_CR6","first-page":"e1248011","volume":"5","author":"SE Langabeer","year":"2016","unstructured":"Langabeer SE. Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics. JAKSTAT. 2016;5:e1248011.","journal-title":"JAKSTAT"},{"key":"3035_CR7","doi-asserted-by":"publisher","first-page":"E264","DOI":"10.1002\/ajh.25580","volume":"94","author":"P Acha","year":"2019","unstructured":"Acha P, Xandri M, Fuster-Tormo F, Palomo L, Xicoy B, Cabez\u00f3n M, et al. Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms. Am J Hematol. 2019;94:E264\u2013E267.","journal-title":"Am J Hematol"},{"key":"3035_CR8","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1111\/bjh.19403","volume":"204","author":"F Ferrer-Mar\u00edn","year":"2024","unstructured":"Ferrer-Mar\u00edn F, Hern\u00e1ndez-Boluda JC, Alvarez-Larr\u00e1n A. Essential thrombocythaemia: a contemporary approach with new drugs on the horizon. Br J Haematol. 2024;204:1605\u201316.","journal-title":"Br J Haematol"},{"key":"3035_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.75","volume":"6","author":"A Angona","year":"2016","unstructured":"Angona A, Fern\u00e1ndez-Rodr\u00edguez C, Alvarez-Larr\u00e1n A, Camacho L, Longar\u00f3n R, Torres E, et al. Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing. Blood Cancer J. 2016;6:e463.","journal-title":"Blood Cancer J"},{"key":"3035_CR10","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379:1416\u201330.","journal-title":"N Engl J Med"},{"key":"3035_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97106-9","volume":"11","author":"T Inano","year":"2021","unstructured":"Inano T, Araki M, Morishita S, Imai M, Kihara Y, Okuda M, et al. Cell-autonomous megakaryopoiesis associated with polyclonal hematopoiesis in triple-negative essential thrombocythemia. Sci Rep. 2021;11:17702.","journal-title":"Sci Rep"},{"key":"3035_CR12","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.3324\/haematol.2022.280917","volume":"107","author":"S Lemoine","year":"2022","unstructured":"Lemoine S, Mornet C, Quintin-Roue I, Rousselet M-C, Cottin L, Georgeais A, et al. Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis. Haematologica. 2022;107:2725\u201331.","journal-title":"Haematologica"},{"key":"3035_CR13","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/bjh.19643","volume":"205","author":"AL Godfrey","year":"2024","unstructured":"Godfrey AL, Sousos N, Frewin R, Prahladan M, Green AC, McGregor A, et al. Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practice. Br J Haematol. 2024;205:1411\u20136.","journal-title":"Br J Haematol"},{"key":"3035_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41588-023-01638-x","volume":"56","author":"J Guo","year":"2024","unstructured":"Guo J, Walter K, Quiros PM, Gu M, Baxter EJ, Danesh J, et al. Inherited polygenic effects on common hematological traits influence clonal selection on JAK2 V617F and the development of myeloproliferative neoplasms. Nat Genet. 2024;56:273\u201380.","journal-title":"Nat Genet"},{"key":"3035_CR15","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057\u201369.","journal-title":"Leukemia"},{"key":"3035_CR16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1412098","volume":"372","author":"CA Ortmann","year":"2015","unstructured":"Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372:601\u201312.","journal-title":"N Engl J Med"},{"key":"3035_CR17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/jclinpath-2020-206570","volume":"74","author":"O Michail","year":"2021","unstructured":"Michail O, McCallion P, McGimpsey J, Hindley A, Greenfield G, McAllister R, et al. Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort. J Clin Pathol. 2021;74:808\u201311.","journal-title":"J Clin Pathol"},{"key":"3035_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36:310\u20138.","journal-title":"J Clin Oncol"},{"key":"3035_CR19","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS701 Version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36:1769\u201370.","journal-title":"J Clin Oncol"},{"key":"3035_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","volume":"189","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189:291\u2013302.","journal-title":"Br J Haematol"},{"key":"3035_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","volume":"127","author":"JD Milosevic Feenstra","year":"2016","unstructured":"Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016;127:325\u201332.","journal-title":"Blood"},{"key":"3035_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","volume":"127","author":"X Cabagnols","year":"2016","unstructured":"Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016;127:333\u201342.","journal-title":"Blood"},{"key":"3035_CR23","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1111\/bjh.16988","volume":"192","author":"A Alvarez-Larr\u00e1n","year":"2021","unstructured":"Alvarez-Larr\u00e1n A, Angona A, Andrade-Campos M, Soledad Noya M, Teresa G\u00f3mez-Casares M, Cuevas B, et al. Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. Br J Haematol. 2021;192:988\u201396.","journal-title":"Br J Haematol"},{"key":"3035_CR24","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1038\/s41375-024-02416-2","volume":"38","author":"M Santaliestra","year":"2024","unstructured":"Santaliestra M, Garrote M, Noya MS, P\u00e9rez-Encinas M, Sen\u00edn A, P\u00e9rez-L\u00f3pez R, et al. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia. Leukemia. 2024;38:2636\u201343.","journal-title":"Leukemia"},{"key":"3035_CR25","doi-asserted-by":"publisher","first-page":"E936","DOI":"10.1097\/HS9.0000000000000936","volume":"7","author":"A Alvarez-Larr\u00e1n","year":"2023","unstructured":"Alvarez-Larr\u00e1n A, Cuevas B, Velez P, Noya S, Caballero-Navarro G, Ferrer-Mar\u00edn F, et al. Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia. Hemasphere 2023;7:E936.","journal-title":"Hemasphere"},{"key":"3035_CR26","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1182\/bloodadvances.2022008204","volume":"7","author":"G Carre\u00f1o-Tarragona","year":"2022","unstructured":"Carre\u00f1o-Tarragona G, Alvarez-Larran A, Harrison CN, Mart\u00ednez-\u00c1vila JC, Hernandez-Boluda, JC, Ferrer-Marin F et al. CNL and aCML should be considered as single entity based on molecular profiles and outcomes. Blood Adv. 2022;7:1672\u201381.","journal-title":"Blood Adv"},{"key":"3035_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/bjh.70260","volume":"208","author":"AL Godfrey","year":"2026","unstructured":"Godfrey AL, Khan AA, McGregor A, Innes AJ, Altohami M, Cross NCP et al. Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations: A British Society for Haematology Guideline. Br J Haematol 2026;208:471\u201385.","journal-title":"Br J Haematol"},{"key":"3035_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and Guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagnostics. 2017;19:4\u201323.","journal-title":"J Mol Diagnostics"},{"key":"3035_CR29","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H. A new look at the statistical model identification. IEEE Trans Autom Contr. 1974;19:716\u201323.","journal-title":"IEEE Trans Autom Contr"},{"key":"3035_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"YosefHochberg Yoav Benjamin","year":"1995","unstructured":"Yoav Benjamin, Yosef Hochberg. Controlling the False Discovery Rate: a practical and powerful approach to multiple testing. J Royal Stat Soc. 1995;57:289\u2013300.","journal-title":"J Royal Stat Soc"},{"key":"3035_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41375-023-02114-5","volume":"38","author":"H Pasquer","year":"2024","unstructured":"Pasquer H, Daltro de Oliveira R, Vasseur L, Soret-Dulphy J, Maslah N, Zhao LP, et al. Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification. Leukemia. 2024;38:326\u201339.","journal-title":"Leukemia"},{"key":"3035_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00968-7","volume":"14","author":"GG Loscocco","year":"2024","unstructured":"Loscocco GG, Gesullo F, Capecchi G, Atanasio A, Maccari C, Mannelli F, et al. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience. Blood Cancer J. 2024;14:10.","journal-title":"Blood Cancer J"},{"key":"3035_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00972-x","volume":"14","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Al-Kali A, Begna KH, Elliott MA, Wolanskyj-Spinner AP, et al. One thousand patients with essential thrombocythemia: the Mayo Clinic experience. Blood Cancer J. 2024;14:11.","journal-title":"Blood Cancer J"},{"key":"3035_CR34","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1038\/leu.2015.249","volume":"29","author":"S Swierczek","year":"2015","unstructured":"Swierczek S, Lima LT, Tashi T, Kim SJ, Gregg XT, Prchal JT. Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms. Leukemia. 2015;29:2432\u20134.","journal-title":"Leukemia"},{"key":"3035_CR35","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1182\/bloodadvances.2020003172","volume":"5","author":"S Alimam","year":"2021","unstructured":"Alimam S, Villiers W, Dillon R, Simpson M, Runglall M, Smith A, et al. Patients with triple-negative, JAK2V617F- A nd CALR-mutated essential thrombocythemia share a unique gene expression signature. Blood Adv. 2021;5:1059\u201368.","journal-title":"Blood Adv"},{"key":"3035_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.","journal-title":"Blood Cancer J"},{"key":"3035_CR37","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"F Visseren","year":"2021","unstructured":"Visseren F, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227\u2013337.","journal-title":"Eur Heart J"},{"key":"3035_CR38","doi-asserted-by":"publisher","first-page":"E578","DOI":"10.1097\/HS9.0000000000000578","volume":"5","author":"SN Constantinescu","year":"2021","unstructured":"Constantinescu SN, Vainchenker W, Levy G, Papadopoulos N. Functional consequences of mutations in myeloproliferative neoplasms. Hemasphere. 2021;5:E578.","journal-title":"Hemasphere"},{"key":"3035_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41408-021-00583-4","volume":"11","author":"LN Varghese","year":"2021","unstructured":"Varghese LN, Carre\u00f1o-Tarragona G, Levy G, Guti\u00e9rrez-L\u00f3pez de Oc\u00e1riz X, Rapado I, Mart\u00ednez-L\u00f3pez J, et al. MPL S505C enhances driver mutations at W515 in essential thrombocythemia. Blood Cancer J. 2021;11:2\u20134.","journal-title":"Blood Cancer J"},{"key":"3035_CR40","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1182\/blood-2016-02-698951","volume":"128","author":"K Kapralova","year":"2016","unstructured":"Kapralova K, Horvathova M, Pecquet C, Kucerova JF, Pospisilova D, Leroy E, et al. Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia. Blood. 2016;128:1418\u201323.","journal-title":"Blood"},{"key":"3035_CR41","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1038\/s41375-021-01239-9","volume":"35","author":"G Carre\u00f1o-Tarragona","year":"2021","unstructured":"Carre\u00f1o-Tarragona G, Varghese LN, Sebasti\u00e1n E, G\u00e1lvez E, Mar\u00edn-S\u00e1nchez A, L\u00f3pez-Mu\u00f1oz N, et al. A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline. Leukemia. 2021;35:3295\u20138.","journal-title":"Leukemia"},{"key":"3035_CR42","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1182\/blood-2013-05-504555","volume":"123","author":"C Marty","year":"2014","unstructured":"Marty C, Saint-Martin C, Pecquet C, Grosjean S, Saliba J, Mouton C, et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood. 2014;123:1372\u201383.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03035-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03035-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03035-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:03:05Z","timestamp":1787684585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03035-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3035"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03035-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was approved by Hospital del Mar (GEE-AAS-2015-01) and Hospital Universitario 12 de Octubre Ethics Committees (21\/378) and conducted in accordance with the Declaration of Helsinki. Informed consent was obtained for all patients.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}